Niagen Bioscience, Inc.
NAGE
$10.04
$0.010.10%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 116.30M | 107.93M | 99.60M | 91.67M | 85.58M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 116.30M | 107.93M | 99.60M | 91.67M | 85.58M |
| Cost of Revenue | 42.31M | 40.46M | 38.01M | 35.34M | 33.53M |
| Gross Profit | 73.99M | 67.46M | 61.59M | 56.33M | 52.06M |
| SG&A Expenses | 51.89M | 49.05M | 47.84M | 50.02M | 48.55M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 99.63M | 94.70M | 91.87M | 91.22M | 87.89M |
| Operating Income | 16.67M | 13.23M | 7.73M | 447.00K | -2.30M |
| Income Before Tax | 18.33M | 14.58M | 8.86M | 1.49M | -1.35M |
| Income Tax Expenses | 601.00K | 473.00K | 305.00K | -- | -- |
| Earnings from Continuing Operations | 17.73 | 14.11 | 8.55 | 1.49 | -1.35 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.73M | 14.11M | 8.55M | 1.49M | -1.35M |
| EBIT | 16.67M | 13.23M | 7.73M | 447.00K | -2.30M |
| EBITDA | 17.45M | 14.02M | 8.54M | 1.29M | -1.39M |
| EPS Basic | 0.23 | 0.18 | 0.11 | 0.02 | -0.02 |
| Normalized Basic EPS | 0.15 | 0.12 | 0.07 | 0.01 | -0.01 |
| EPS Diluted | 0.21 | 0.17 | 0.10 | 0.01 | -0.02 |
| Normalized Diluted EPS | 0.14 | 0.11 | 0.07 | 0.01 | -0.01 |
| Average Basic Shares Outstanding | 309.98M | 306.29M | 303.71M | 301.88M | 300.96M |
| Average Diluted Shares Outstanding | 328.92M | 318.24M | 310.24M | 303.69M | 300.97M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |